基于早期反应评估的治疗修改是否可以改善DLBCL的结果?
Hari S Raman1, Jennifer L Crombie1
1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Hematology. American Society of Hematology. Education Program
|December 5, 2025
概括
早期识别高风险的扩散性大B细胞淋巴瘤 (DLBCL) 患者至关重要. 虽然临时正子发射断层扫描显示出有限的成功,但评估最小残留疾病 (MRD) 为DLBCL提供了有前途的个性化治疗策略.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 医疗成像医学成像
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 尽管接受了前线治疗,但其复发率很高.
- 目前的复发治疗是密集的,并非普遍有效.
- 需要确定高风险患者进行修改的初始策略或低风险患者进行降级.
研究的目的:
- 审查中期正子发射断层扫描 (PET) 在DLBCL中的预后作用.
- 评估最小残留疾病 (MRD) 评估的潜力,以指导DLBCL治疗.
- 讨论DLBCL临床试验中MRD的未来方向.
主要方法:
- 对DLBCL的预后成像和分子标记物的文献综述.
- 分析使用临时PET进行反应评估的研究.
- 对DLBCL中MRD检测现有和新兴方法的审查.
主要成果:
- 临时PET具有预后价值,但在很大程度上未能有效地指导适应性治疗.
- 最小残留性疾病 (MRD) 显示出在DLBCL中作为早期治疗反应的敏感标记物的潜力.
- 对于MRD评估,有各种工具和技术可用,并且在不断发展.
结论:
- 在DLBCL中,以早期反应为指导的个性化治疗方法具有前景,但需要进一步的临床验证.
- 评估MRD是未来研究的关键领域,以优化DLBCL治疗策略.
- 未来的DLBCL试验应该包括MRD评估,以改进治疗决策并改善患者的治疗结果.
更多相关视频
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
30.3K
09:44Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
10.5K
相关概念视频
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
